Spyre Therapeutics, Inc. · NASDAQ:SYRE

Burrows Scott L sold 25,000 Spyre Therapeutics, Inc. shares (Form 4)

Traded Sep 30 to Oct 1, 2026 · Filed Oct 2, 2026

From Sep 30 to Oct 1, 2026, Burrows Scott L (Chief Financial Officer) sold 25,000 Spyre Therapeutics, Inc. shares at an average US$90.47 for US$2.26M under a trading plan, leaving 79,762 shares. Filed Oct 2, 2026 (Form 4).

Sold
25,000 shares
Price
US$90.47 average (US$89.07 to US$93.57)
Value
US$2.26M
Holding after
79,762 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Sep 30, 2026Common StockOption exercise17,500US$14.5097,262Direct
Sep 30, 2026Common StockSale17,500US$89.8979,762Direct
Oct 1, 2026Common StockOption exercise7,500US$14.5087,262Direct
Oct 1, 2026Common StockSale600US$89.0786,662Direct
Oct 1, 2026Common StockSale1,500US$90.2785,162Direct
Oct 1, 2026Common StockSale2,100US$91.9283,062Direct
Oct 1, 2026Common StockSale3,071US$92.9579,991Direct
Oct 1, 2026Common StockSale229US$93.5779,762Direct

Source

View original at SEC

Related